Michael Bergamini brings over 30 years of experience in the eye care industry. He is an experienced biomedical R&D executive and a leader of pre-clinical and clinical functions and project teams. He has played key roles in the discovery, translation, development, registration, and US and International launch of a dozen pharmaceuticals, as well as several medical device products. Dr. Bergamini has served at the University of North Texas Health Science Center as an Adjunct Professor of Pharmacology & Neuroscience since the late 1990’s, as Director, Office of Clinical Trials from 2009 to 2011, and as Executive-in- Residence and Senior Research Analyst from 2011 to 2014. From 1997 to 2009, he held several senior positions with Alcon Research Ltd., the world’s leader in eye care, including Vice President, Pharmaceutical Development and Glaucoma Development. Prior to its acquisition by Alcon, Dr. Bergamini was Chief Executive Officer of the R&D center for Laboratorios Cusí, S.A., the Spanish market leader in ophthalmic therapeutics & surgical adjuncts. He previously was Vice President of R&D at SOLA/Barnes-Hind, Director of Ophthalmic R&D at the Liposome Company, Inc., and Manager of Pharmacology at Allergan Pharmaceuticals, Inc. Dr Bergamini holds a PhD in Pharmacology (Biomedical Sciences) from the City University of New York. He is the author of 35 peer-reviewed publications, as well as a number of book chapters and more than a dozen patents.

 Glaucoma, Ophthalmology, Pharmaceuticals,